# Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age

> **NCT02418455** · PHASE2 · COMPLETED · sponsor: **Ultragenyx Pharmaceutical Inc** · enrollment: 8 (actual)

## Conditions studied

- Sly Syndrome
- MPS VII
- Mucopolysaccharidosis
- Mucopolysaccharidosis VII

## Interventions

- **DRUG:** UX003

## Key facts

- **NCT ID:** NCT02418455
- **Lead sponsor:** Ultragenyx Pharmaceutical Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-07-21
- **Primary completion:** 2019-03-26
- **Final completion:** 2019-03-26
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2019-10-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02418455

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02418455, "Study of UX003 Recombinant Human Beta-Glucuronidase (rhGUS) Enzyme Replacement Treatment in Mucopolysaccharidosis Type 7, Sly Syndrome (MPS 7) Patients Less Than 5 Years of Age". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02418455. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*